Govt waives import duty on Remdesivir

Amid surging COVID-19 cases in the country, the government on Tuesday waived customs duty on Remdesivir, its raw materials and other components used to make the antiviral drug. The move would help......

3 lakh remdesivir to be produced daily in 15 days: Govt

The government plans to double the production of antiviral drug remdesivir to around 3 lakh vials per day over the next 15 days, to make it available readily for the treatment of COVID-19.......

Cipla to price Remdesivir for Covid-19 under Rs 5,000

Hetero has priced the injectable drug at Rs 5,400 per 100 mg vial. With more drugmakers in line to launch the drug soon, the prices may see a further erosion. Sohini Das reports. IMAGE: An......

India-made Remdesivir may come out in 10 days

The antiviral drug may cost around Rs 55,000 for an 11-dose course, or Rs 5,000 per injection -- much less than the price of imports from Bangladesh, reports Sohini Das.  Image used for......

Matrix move to give 10% more to Mylan

To allow its new promoters to pick up an extra 10 per cent stake, Matrix Laboratories is planning a $100 million foreign currency convertible bond issue.US-based Mylan Laboratories had acquired the......

Mylan acquires 51.5% in Matrix

US-based Mylan Laboratories Inc has acquired around 51.5 per cent stake in pharmaceutical company Matrix Laboratories for Rs 306 per share. With the completion of the deal, M P Laboratories......

Daiichi to take on Mylan, Teva

Daiichi-Sankyo's $5.3 billion acquisition of India's biggest drugmaker will help the Japanese company compete in the US markets with rivals such as Mylan and Israel-based Teva Pharmaceuticals and......

Biocon pitches for global top 3 slot

Biocon was scouting for more strategic alliances and exploring opportunities for outlicensing its biotech drugs under development, as it pitches for a slot among the top three bio-pharmaceutical......